I agree with the failed trial description.
However, I question whether .50 is an accurate price for a company that will (in all likelyhood) have to run at least 1 and possibly 2 more Phase III trials ($5M cost if I recall), has no money now so will have to raise money, raised the previous $5M via a "toxic death spiral" financing, has a lawsuit pending against an earlier previous financing partner alleging illegal short selling of CLSC, and whom Cobalis still owes money to, and is likely to spend x months and x dollars in a losing cause trying to salvage the data from these 2 trials.
IMO, selling for .48 right now is the right choice, but as always time will tell.
There will undoubtedly be trading opportunities for those nimble enough to guess/predict the right entry and exit points, but to me the longer term writing is clearly on the wall now.
I sold my final shares at .48 a few moments ago.
P.S. My condolences to everyone who, like me, lost some money on this investment. And absolutely good luck to all remaining longs.